chr5-60918364-G-C
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000082.4(ERCC8):āc.300C>Gā(p.Tyr100*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000168 in 1,608,864 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000082.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ERCC8 | NM_000082.4 | c.300C>G | p.Tyr100* | stop_gained | 4/12 | ENST00000676185.1 | NP_000073.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ERCC8 | ENST00000676185.1 | c.300C>G | p.Tyr100* | stop_gained | 4/12 | NM_000082.4 | ENSP00000501614.1 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 151966Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000160 AC: 4AN: 249862Hom.: 0 AF XY: 0.00000740 AC XY: 1AN XY: 135058
GnomAD4 exome AF: 0.0000151 AC: 22AN: 1456898Hom.: 0 Cov.: 28 AF XY: 0.0000152 AC XY: 11AN XY: 725032
GnomAD4 genome AF: 0.0000329 AC: 5AN: 151966Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74228
ClinVar
Submissions by phenotype
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 02, 2023 | This sequence change creates a premature translational stop signal (p.Tyr100*) in the ERCC8 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ERCC8 are known to be pathogenic (PMID: 29572252). This variant is present in population databases (rs143367518, gnomAD 0.004%). This premature translational stop signal has been observed in individual(s) with Cockayne syndrome (PMID: 19309286). ClinVar contains an entry for this variant (Variation ID: 371025). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Dec 06, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Nov 03, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 08, 2023 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 25525159, 34426522, 31589614, 32404165, 19309286) - |
Cockayne syndrome type 1 Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | Counsyl | Nov 03, 2016 | - - |
Cockayne syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 08, 2022 | Variant summary: ERCC8 c.300C>G (p.Tyr100X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic in HGMD and ClinVar. The variant allele was found at a frequency of 1.6e-05 in 249862 control chromosomes. c.300C>G has been reported in the literature in individuals affected with Cockayne Syndrome (e.g. Conte_2009, Issa_2020). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four ClinVar submitters (evaluation after 2014) have cited the variant with three submitters classifying the variant as pathogenic and one submitter classifying the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Cockayne syndrome type 1;C3553298:UV-sensitive syndrome 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 04, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at